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1. Introduction 
Vitamin B12 deficiency remains a worldwide health problem in the 21st century. The advent 
of metabolite assays in the last few decades further expands the population with subclinical 
or tissue deficiency and thus the magnitude of the problem. The increasing recognition of its 
association with the use of metformin raises another controversy for clinicians regarding 
detection and treatment of vitamin B12 deficiency. Since the clinical use of metformin in 
1957, malabsorption of vitamin B12 in diabetic patients treated with metformin was first 
noted in 1969 (Berchtold et al., 1969). Subsequent studies revealed both short-term and long-
term use of metformin induces malabsorption of vitamin B12 and causes decreased serum 
vitamin B12 concentrations in 10% to 30% of diabetic patients (Tomkin et al., 1971; Bauman 
et al., 2000; Wulffele el al., 2003; Hermann et al., 2004). A randomized placebo controlled 
Dutch trial recently reconfirmed this finding and demonstrated treatment with metformin 
for a mean of 4.3 years resulted not only in a 19% persistent and progressive reduction of 
mean serum vitamin B12 concentrations, but also raised serum homocysteine concentrations 
(de Jager et al., 2010). Other case-control and cross-sectional studies identified duration and 
dosage of metformin use as risk factors for vitamin B12 deficiency (Ting et al., 2006). It is 
believed that if individuals with type 2 diabetes receiving metformin develop low serum 
vitamin B12 concentrations, a stage of asymptomatic tissue deficiency, would eventually 
progress to symptomatic clinical deficiency, as evidenced by reports of megaloblastic 
anaemia caused by metformin-related vitamin B12 malabsorption, unless they are duly 
treated (Gilligan, 2002; Filioussi et al., 2003; Liu et al., 2006). 
Metformin is now extensively used as the first line pharmacological agent for glycaemic 
control especially following the favourable results of the United Kingdom Prospective 
Diabetes Study (UKPDS 34) in 1998. This coupled with the rising incidence of type 2 
diabetes in many parts of the world constitutes a driving force for relevant parties to make 
appropriate recommendations or guidelines concerning the detection and treatment of 
vitamin B12 deficiency among diabetic patients on metformin. Although the haematological 
and neurological manifestations of overt or clinical vitamin B12 deficiency are easy to 
diagnose, they are often overlooked and attributed to diabetic complications or aging 
among diabetic patients.  
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The present study attempts to address the issue from the end spectrum of the disorder - 
florid vitamin B12 deficiency in type 2 diabetic patients. Through description and analysis of 
the clinical manifestations of overt vitamin B12 deficiency in a cohort of adult Chinese 
patients with type 2 diabetes, and delineation of the underlying aetiology of vitamin B12 
deficiency, the study aims to highlight the characteristics of vitamin B12 deficiency in type 2 
diabetic patients, and to evaluate the implications of metformin use in relation to the 
development of vitamin B12 deficiency of undetermined origin in diabetic patients. 
2. Materials and methods 
2.1 Patient source and stratification 
The patient source was from a longitudinal study of adult Chinese patients (≥ 18 years) 
presenting with megaloblastic anaemia and/or neurological deficits in association with low 
serum vitamin B12 levels serially encountered in a regional hospital in Hong Kong between 
May 1994 and October 2010 (Chan et al., 2008). According to whether they had type 2 diabetes 
as shown by the diagnostic codes in the medical records at the time of diagnosis of vitamin B12 
deficiency, patients were stratified into diabetic and non-diabetic groups. Documentation of 
diagnosis of diabetes was at the discretion of in-charge physicians and the diagnostic criteria of 
World Health Organization (WHO, 1999) with fasting plasma glucose ≥7.0 mmol/L or 2-hour 
post prandial plasma glucose ≥11.1 mmol/L were adopted. Diabetes both with and without 
complications were included. Diabetic patients were further stratified according to whether 
they were on metformin at the time of diagnosis of vitamin B12 deficiency. Diabetic patients 
who had been on metformin for one or more years immediately before the diagnosis of 
vitamin B12 deficiency were counted as metformin users and assigned to the “on metformin” 
group. Other diabetic patients on dietary control, insulin, sulphonylureas, metformin for less 
than one year or longer period but having stopped in the one year before the diagnosis of 
vitamin B12 deficiency, were assigned to the “not on metformin” group.  
2.2 Data collection and analysis 
Baseline data were retrieved from patients’ medical records and investigators’ file of adult 
Chinese patients with vitamin B12 deficiency. Data entry included presenting clinical and 
laboratory features at the time of diagnosis of vitamin B12 deficiency; causes of vitamin B12 
deficiency; medications including metformin, sulphonylureas, insulin, proton pump inhibitors 
(PPI), histamine 2 blockers (H2B), lipid lowering agents, antiplatelet agents, antihypertensive 
and cardiac agents; duration of metformin use; and duration of  diabetic history. 
The sequence of data analysis was shown in Box 1. (i) The presenting features and the 
causes of vitamin B12 deficiency were compared between patients with and without type 2 
diabetes. The odds ratio (OR) of developing vitamin B12 deficiency of undetermined origin 
among diabetic patients to non-diabetic patients was determined. (ii) The presenting 
features and the causes of vitamin B12 deficiency were compared between type 2 diabetic 
patients “on metformin” and diabetic patients “not on metformin”. The OR of developing 
vitamin B12 deficiency of undetermined origin among diabetic patients “on metformin” to 
patients “not on metformin” was determined. (iii) For diabetic patients with undetermined 
aetiology of vitamin B12 deficiency, the presenting features and the medications prescribed 
at the time of diagnosis of vitamin B12 deficiency were compared between those “on 
metformin” and those “not on metformin”. (iv) The duration of metformin use in relation to 
the onset of vitamin B12 deficiency was studied among all diabetic patients on metformin, 
irrespective of the underlying aetiology of vitamin B12 deficiency.  
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2.3 Definitions  
Known causes of vitamin B12 deficiency include (i) pernicious anaemia (PA) defined by the 
presence of serum intrinsic factor (IF) antibody and/or by abnormal Schilling test 
compatible with immune loss of IF; (ii) probable PA (PPA) defined by the absence of 
demonstrable IF antibody, no performance of Schilling test, and the presence of at least 2 out 
of 3 immune features – gastric parietal cell (GPC) antibody, antithyroid antibodies, and 
histological evidence of autoimmune gastropathy (J.C.W. Chan & F.H.Y. Chan, 2011); (iii) 
gastrointestinal disorders such as total gastrectomy and terminal ileal resection or diseases 
e.g. Crohn’s disease, ulcerative colitis; (iv) nutritional deficiency in strict vegetarians. Only 
after excluding PA and PPA, the first two overriding causes, gastrointestinal and nutritional 
causes are considered.  
The cause of vitamin B12 deficiency is considered to be undetermined if none of the above 
conditions are present. Common predisposing factors for the development of vitamin B12 
deficiency of undetermined causes include food cobalamin malabsorption, idiopathic gastric 
atrophy, Helicobacter pylori (HP) associated gastritis, use of PPI and H2B, metformin 
related malabsorption of vitamin B12, and a multitude of other conditions all of which 
currently lack easily available confirmatory tools and are diagnosed largely by exclusion. 
Known causes of vitamin B12 deficiency and the diagnostic approach to arrive at the 
conclusion of undetermined aetiology of vitamin B12 deficiency are summarized in Box 2. 
2.4 Measurements 
Serum cobalamin was measured with a fluorometric method using Abbott IMX analyzer 
(Abbott Laboratory, Chicago, IL) from 1994 to 2002; and with a chemiluminescent 
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immunoassay using paramagnetic particles of Access Immunoassay System (Beckman 
Coulter, Fullerton, CA) from 2003 to 2010. Reference range for serum vitamin B12 level was 
132–835 pmol/L from 1994 to 2002, and 180–914 ng/L from 2003 to 2010. To facilitate 
analysis, serum vitamin B12 levels in pmol/L were converted to ng/L by using the 
equation, 1 pmol/L=1.355 ng/L, (molecular mass of vitamin B12=1355 mol/g). Vitamin B12 
deficiency was defined by serum vitamin B12 levels below 132 pmol/L or below 180 ng/L. 
 
Box 2:   Aetiology of vitamin B12 deficiency 
Known causes Undetermined causes (diagnostic steps) 
(i) pernicious anaemia (i) exclusion of known causes 
(ii) probable pernicious anaemia (ii) examples of predisposing factors:        
(iii) gastrointestinal disorders food cobalamin malabsorption, gastric atrophy, 
(iv) malnutrition Helicobacter pylori infection, long-term ingestion of 
metformin, proton pump inhibitor,  histamine 2 blocker 
2.5 Statistical analysis  
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS Inc, Chicago, Illinosis, USA), version 15. Data were reported as means and standard 
deviation (SD), or as medians and interquartile range (IQR). The chi-square test was used 
for comparison between categorical variables, Student’s t test for continuous variables of 
normal distribution, and Mann-Whitney U test for continuous data of skewed distribution. 
P values of less than 0.05 were considered to indicate statistical significance. Among patients 
with B12 deficiency, a chi-square analysis (two-tailed; two-by-two table) was used to 
estimate the crude OR of having B12 deficiency of undetermined origin among patients with 
type 2 diabetes to those without diabetes, and another chi-square analysis (two-tailed; two-
by-two table) was used to calculate the crude OR of having B12 deficiency of undetermined 
origin among patients taking metformin to the diabetic patients not taking metformin. 
Multivariate analysis using stepwise forward logistic regression were used to identify risk 
factors independently associated with vitamin B12 deficiency of undetermined origin in all 
patients and in diabetic patients; and in diabetic patients on metformin and not on 
metformin. Extended Mantel-Haenzel chi-square analysis was performed for linear trend. 
3. Results 
Between May 1994 and October 2010, 635 adult Chinese patients (excluding 1 patient with 
type 1 diabetes and PA diagnosed at the age of 14 years old) were diagnosed to have overt 
vitamin B12 deficiency in a regional hospital in Hong Kong. At the time of diagnosis of 
vitamin B12 deficiency, 191 (30%) patients had type 2 diabetes, and 444 (70%) were non-
diabetics.  
3.1 Vitamin B12 deficiency: Type 2 diabetic and non-diabetic patients  
Concerning the demographic features (Table 1), 37% of 191 diabetic patients and 44% of 444 
non-diabetic patients were male (p=0.079), and the mean ages of diabetic and non-diabetic 
patients were 75.6 years (SD 9.1) and 72.3 years (SD 14.5) respectively (p=0.001). The clinical 
manifestations of vitamin B12 deficiency were less symptommatic in diabetic than non-
diabetic patients, as evidenced by 34% of diabetic and 47% of non-diabetic patients having 
anaemia (p=0.002), and 3% of diabetic and 7% of non-diabetic patients having peripheral     
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  Number of patients (%)    
 With diabetes 
(n=191) 
No diabetes 
(n=444) 
p 
adjusted 
OR 
95% 
CI 
Demographics      
 Sex, male  70/191 (37) 196/444 (44) 0.079   
 Mean age [SD], years 75.6 [9.1] 72.3 [14.5] 0.001   
Presenting features      
 Anaemia 65/191 (34) 210/444 (47) 0.002   
 PN/SCD1 5/191 (3) 30/444 (7) 0.036   
 Dementia 15/191 (8) 41/444 (9) 0.574   
Laboratory findings      
 Mean Haemoglobin [SD], g/L 9.8 [2.5] 9.0 [2.9] 0.001   
 Mean MCV2 [SD], fl 110.0 [12.1] 113.4 [15.4] 0.003   
 Mean serum B12 level [SD], ng/L 85.8 [38.1] 80.0 [41.9] 0.106   
 Intrinsic Factor Antibody +ve 49/191 (26) 248/444 (56) <0.001   
 GPC3 Antibody +ve 73/191 (38) 245/444 (56) <0.001   
 Anti-thyroid antibody +ve 26/159 (16) 126/337 (37) <0.001   
Thyrogastric features      
 History of AITD4  4/191 (2) 29/444 (7) 0.021   
 Biopsy proven gastric atrophy 25/80 (31) 86/196 (44) 0.052   
 ECH5 0/80 (0) 6/196 (3) 0.114   
 HP6 +ve histology 10/80 (13) 16/196 (8) 0.263   
Aetiology of B12 deficiency      
 Undetermined 129/191 (68) 132/444 (30) <0.001 
 
5.54 3.66 - 
8.38 
Known 62/191 (32) 312/444 (70)   
  Pernicious anaemia 54/191 (28) 265/444 (60) <0.001   
  Probable pernicious anaemia 4/191 (2) 15/444 (3) 0.384   
  Gastrointestinal surgery/disorder 2/191 (1) 24/444 (5) 0.011   
1peripheral neuropathy/subacute combined degeneration   2mean corpuscular volume    
3Gastric Parietal Cell, 4autoimmune thyroid disease,  5Enterochromaffin Cell  Hyperplasia, 6Helicobacter 
pylori 
Table 1. Comparison of presenting features and causes of vitamin B12 deficiency: type 2 
diabetic and non-diabetic patients 
neuropathy and/or subacute combined degeneration of cord (p=0.036). Dementia was the 
presenting feature in 8% of diabetic and 9% of non-diabetic patients (p=0.574). The mean 
haemoglobin (Hb) concentrations of diabetic and non-diabetic patients were 9.8 g/L (SD 2.5) 
and 9.0 g/L (SD 2.9) respectively (p=0.001), and the mean mean corpuscular volume (MCV) 
of the two groups were 110.0 fl (SD 12.1) and 113.4 fl (SD 15.4) respectively (p=0.003). The 
mean serum vitamin B12 levels of diabetic and non-diabetic patients were 85.8 ng/L (SD 
38.1) and 80.0 ng/L (SD 41.9) respectively (p=0.106). Serum IF antibody was detected in 26% 
of diabetic and 56% of non-diabetic patients (p<0.001); GPC antibody in 38% of diabetic and 
56% of non-diabetic patients (p<0.001); and anti-thyroid antibodies in 16% of diabetic and 
37% of non-diabetic patients (p<0.001). History of autoimmune thyroid disease (AITD) was 
obtained in 2% of diabetic and 7% of non-diabetic patients (p=0.021). Endoscopically proven 
gastric atrophy was detected in 31% of diabetic and 44% of non-diabetic patients (p=0.052), 
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enterochromaffin cell hyperplasia (ECH) in 0% of diabetic and 3% of non-diabetic patients 
(p=0.114), and HP organisms in 13% of diabetic and 8% of non-diabetic patients (p=0.263). 
The underlying aetiology of vitamin B12 deficiency was undetermined in 68% of diabetic 
and 30% of non-diabetic patients (p<0.001); due to PA in 28% of diabetic and 60% of non-
diabetic patients (p<0.001); PPA in 2% of diabetic and 3% of non-diabetic patients (p=0.384); 
related to gastrointestinal surgery or disorders in 1% of diabetic and 5% of non-diabetic 
patients (p=0.011); and malnutrition in 1% of diabetic and 2% of non-diabetic patients 
(p=0.484). The percentages of patients with vitamin B12 deficiency of undetermined origin, 
due to PA, and other known causes (PPA, gastrointestinal disorders, malnutrition) among 
diabetic and non-diabetic patients were shown in Figure 1. The crude OR of developing 
vitamin B12 deficiency of undetermined origin in type 2 diabetic patients compared with 
non-diabetic patients was 4.90 (95% CI, 3.41- 7.08). The adjusted OR (adjusted for sex, age, 
use of PPI/H2B) of developing vitamin B12 deficiency of undetermined origin in type 2 
diabetic patients compared with non-diabetic patients was 5.54 (95% CI, 3.66 – 8.38). 
 
 
Fig. 1. Comparison of causes of vitamin B12 deficiency: type 2 diabetic and non-diabetic 
patients 
3.2 Vitamin B12 deficiency: type 2 diabetic patients “on metformin” and “not on 
metformin”  
Among the 191 patients with type 2 diabetes, 5 patients with unclear metformin history 
were excluded from analysis, and 186 patients – 128 (69%) “on metformin” and 58 (31%) 
“not on metformin” were analysed (Table 2). Of the 128 patients “on metformin”, 30% were 
male, and of the 58 patients “not on metformin”, 50% were male (p=0.008). The mean ages of 
patients “on metformin” and “not on metformin” were 75.3 years [SD 9.2] and 76.3 years [SD 
9.2] respectively (p=0.463). Thirty one percent of patients “on metformin” and 36% of patients 
“not on metformin” presented with anaemia (p=0.505); 0.8% of patients “on metformin” and 
7% of patients “not on metformin” had peripheral neuropathy and/or subacute combined 
degeneration of cord (p=0.017), and 9% of patients “on metformin” and 3% of “not on 
metformin” had dementia (p=0.156). The mean Hb concentrations of patients “on metformin”  
and “not on metformin” were 9.9 g/L [SD 2.4] and 9.7 g/L [SD 2.6] respectively (p=0.498), and 
the mean MCV 108.5 fl [SD 12.0] and 112.1 fl [SD 11.9] respectively (p=0.058). The mean serum    
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 Number of diabetic patients (%)   
 
On    
metformin 
(n=128) 
Not on 
metformin 
(n=58) 
p 
adjusted 
OR 
95% 
CI 
Demographics            
 Sex, male  38/128 (30) 29/58 (50) 0.008   
 Mean age [SD], years 75.3 [9.2] 76.3 [9.2] 0.463   
Presenting features      
 Anaemia 40/128 (31) 21/56 (36) 0.505   
 PN/SCD1 1/128 (0.8) 4/58 (7) 0.017   
 Dementia 12/128 (9) 2/58 (3) 0.156   
Laboratory findings       
 Mean Haemoglobin [SD], g/L  9.9 [2.4] 9.7 [2.6] 0.498   
 Mean MCV2 [SD], in fl 108.5 [12.0] 112.1 [11.9] 0.058   
 Mean serum B12 level [SD], ng/L 90.3 [37.6] 76.7 [38.6]  0.026   
 Intrinsic Factor Antibody +ve 20/128 (16) 24/58 (41) <0.001   
 Gastric Parietal Cell Antibody +ve 41/127 (32) 30/58 (52) 0.012   
 Anti-thyroid Antibody +ve 15/115 (13) 11/42 (26) 0.050   
Thyrogastric features      
 History of AITD3  3/128 (2.3) 1/58 (1.7) 0.787   
 Biopsy proven gastric atrophy 8/48 (17) 13/28 (46) 0.005   
 Enterochromaffin Cell Hyperplasia 0/48 (0) 0/28 (0) -   
 Helicobacter pylori +ve histology 8/48 (17) 2/28 (7) 0.236   
Aetiology of B12 deficiency       
 Undetermined 102/128 (80) 27/58 (47)  <0.001 
 
5.20 2.33- 
11.60 
 Known 26/128 (20) 31/58 (53)   
  Pernicious anaemia 22/128 (17) 27/58 (47) <0.001   
  Probable pernicious anaemia 1/128 (0.8) 3/58 (5) 0.384   
  Gastrointestinal surgery/disorder 1/128 (0.8) 1/58 (1.7) 0.011   
  Nutritional 2/128 (1.6) 0/58 (0) 0.484   
Median diabetic duration [IQR], 
years  
10 [6.5-11.5] 
(n=121) 
4 [1.5-8.5] 
(n=41) 
<0.001   
1peripheral neuropathy/subacute combined degeneration    
2mean corpuscular volume 3autoimmune thyroid disease 
Table 2. Comparison of presenting features and causes of vitamin B12 deficiency: type 2 
diabetic patients “on metformin” and “not on metformin” 
B12 levels of patients “on metformin” and “not on metformin” were 90.3 ng/L [SD 37.6] and 
76.7 ng/L [SD 38.6] respectively (p=0.026). Frequencies of IF antibody in the “on metformin” 
and “not on metformin” groups were 16% and 41% respectively (p<0.001), that of GPC 
antibody 32% and 52% respectively (p=0.012), and that of anti-thyroid antibodies 13% and 
26% respectively (p=0.050). History of AITD was obtained in 2.3% of patients “on 
metformin” and 1.7% of patients “not on metformin” (p=0.787). Histological evidence of 
gastric atrophy was detected in 17% of patients “on metformin” and 46% of patients “not on 
metformin” (p=0.005), ECH in none of the patients in the two groups, and HP organisms in 
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17% of patients “on metformin” and 7% of patients “not on metformin” (p=0.236). The 
median duration of diabetic history for those “on metformin” (n=121) and “not on 
metformin” (n=41) were 10 years [IQR 6.5-11.5] and 4 years [IQR 1.5-8.5] respectively 
(p<0.001). 
Of the 128 diabetic patients “on metformin” and 58 diabetic patients “not on metformin”, 
the causes of vitamin B12 deficiency were undetermined in 80% of patients “on metformin” 
and in 47% of those “not on metformin” (p<0.001); due to PA in 17% of patients “on 
metformin” and 47% of “not on metformin” (p<0.001); PPA in 0.8% of patients “on 
metformin” and 5% of “not on metformin” (p=0.384); due to gastrointestinal disorders in 
0.8% and 1.6% of patients “on metformin” and “not on metformin” respectively (p=0.011), 
and due to malnutrition in 1.5% and 0% of patients “on metformin” and “not on metformin” 
respectively (p=0.484). The percentages of patients with vitamin B12 deficiency of 
undetermined origin, due to PA, and other known causes (PPA, gastrointestinal disorders, 
malnutrition) among non-diabetic patients, diabetic patients “on metformin”, and diabetic 
patients “not on metformin” were shown in Figure 2. The crude OR of developing vitamin 
B12 deficiency of undetermined origin in type 2 diabetic patients “on metformin” compared 
with diabetic patients “not on metformin” was  4.50 (95% CI, 2.30 - 8.82). The adjusted OR 
(adjusted for sex, age, use of PPI/H2B) of developing vitamin B12 deficiency of 
undetermined origin in type 2 diabetic patients “on metformin” compared with diabetic 
patients “not on metformin” was  5.20 (95% CI, 2.33 - 11.60).  
     
 
 
Fig. 2. Comparison of causes of vitamin B12 deficiency: diabetic patients on metformin and 
not on metformin, non-diabetic patients 
3.3 Vitamin B12 deficiency of undetermined origin: “on metformin” and “not on 
metformin”  
Of the 191 diabetic patients with vitamin B12 deficiency, 62 patients (including 5 with 
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patients, 129 diabetic patients had vitamin B12 deficiency of undetermined aetiology - 102 
(79%) “on metformin” and 27 (21%) “not on metformin” at the time of diagnosis of vitamin 
B12 deficiency (Table 3). Thirty two percent of patients “on metformin” were male, and 44% 
of patients “not on metformin” were male (p=0.241). The mean ages of patients “on 
metformin” and “not on metformin” were 76.4 years [SD 8.2] and 77.1 years [SD 10.3] 
respectively (p=0.721). Anaemia was the presenting feature in 25% of patients “on metformin”  
 
 
                                                       Number of patients (%) 
 
On metformin 
(n=102) 
Not on metformin 
(n=27) 
P 
Demographics    
Sex, male  33/102 (32) 12/27 (44) 0.241 
Mean age [SD], in years 76.4 [8.2] 77.1 [10.3] 0.721 
Presenting features    
Anaemia 25/102 (25) 8/27 (30) 0.588 
PN/SCD1 1/102 (1) 3/27 (11) 0.007 
Dementia 9/102 (9) 1/27 (4) 0.376 
Laboratory findings    
Mean Haemoglobin [SD], g/L 10.2 [2.2] 10.2 [2.4] 0.988 
Mean MCV2 [SD], fl 107.3 [11.1] 108.2 [11.3] 0.706 
Mean serum B12 level [SD], ng/L 93.7 [38.1]  86.0 [43.5] 0.369 
Gastric Parietal Cell Antibody +ve 24/101(24) 12/27 (44) 0.034 
Anti-thyroid Antibody +ve 11/91 (12) 0/18 (26) 0.120 
Thyrogastric features    
History of AITD3 1/102 (1) 0/27 (0) 0.606 
Biopsy proven gastric atrophy 2/39 (5) 3/13 (23) 0.057 
Enterochromaffic Cell Hyperplasia 0/39 (0) 0/13 (0) - 
Helicobacter pyloria +ve histology 8/39 (21) 1/13 (8) 0.290 
Median diabetic duration [IQR] in 
years   
10 [6-10] (n=99) 3.5 [1.3-6.8] (n=20) <0.001 
Diabetic medications    
 Sulph4+metformin*    Sulph4 alone** 54/102 (53)* 11/27 (41)** 0.260 
 Insulin+metformin*   Insulin alone** 9/102 (9)* 1/27 (4)**  0.376 
 Metformin alone 39/102 (38) -  
 Nil anti-diabetic medication - 15/27 (55)  
Other concomitant medications    
PPI/H2B5 26/101 (26) 9/26 (35) 0.815 
Anti-platelet agents 42/101 (42) 6/26 (23) 0.083 
Lipid lowering agents 28/101 (28) 3/26 (12) 0.087 
Hypertensive/cardiac agents 88/101 (87) 18/26 (69) 0.028 
1peripheral neuropathy/subacute combined degeneration 2mean corpuscular volume 
3autoimmune thyroid disease   
4sulphonylurea  5proton pump inhibitor/ histamine 2 blocker 
Table 3. Comparison of presenting features and medications of diabetic patients with 
vitamin B12 deficiency of undetermined aetiology: “on metformin” and “not on metformin” 
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and 30% of patients “not on metformin” (p=0.588), peripheral neuropathy/subacute combined 
degeneration of cord in 1% of patients “on metformin” and 11% of patients “not on 
metformin” (p=0.007), and dementia in 9% of patients “on metformin” and 4% of patients  
“not on metformin” (p=0.376). The mean Hb concentrations of those “on metformin” and “not 
on metformin” were 10.2 g/L [SD 2.2] and 10.2 g/L [SD 2.4] respectively (p=0.988), the mean 
MCV of the two groups were 107.3 fl [SD 11.1] and 108.2 fl [SD 11.3] respectively (p=0.706), 
and the mean serum vitamin B12 levels were 93.7 ng/L [SD 38.1] and 86.0 ng/L [SD 43.5] 
respectively (p=0.369). GPC antibody was detected in 24% of patients “on metformin” and 
44% of patients “not on metformin” (p=0.034), and anti-thyroid antibodies in 12% and 26% of 
the two groups respectively (p=0.120). AITD occurred in 1% of patients “on metformin” and 
none of the patients “not on metformin” (p=0.606). Histology of gastric atrophy was detected 
in 5% of patients “on metformin” and 23% of patients “not on metformin” (p=0.057), ECH in 
none of the patients in the two groups, and histological evidence of HP organisms in 21% and 
8% of the two groups respectively (p=0.290).  
The median duration of diabetes for the “on metformin” (n=99) and “not on metformin” 
(n=20) patients were 10 years [IQR 6-10] and 3.5 years [IQR 1.3-6.8] respectively (p<0.001). 
Fifty three percent of the “on metformin” patients were also on sulphonylureas, and 41% of 
the “not on metformin” patients were on sulphonylurea alone (p=0.260). Nine percent of the 
“on metformin” patients were also on insulin, and 4% of the “not on metformin” patients 
were on insulin alone (p=0.376). Thirty eight percent of the “on metformin” patients were on 
metformin alone, and 55% of the “not on metformin” patients were not on any diabetic 
agents – 4 chronic renal insufficiency, 2 early deaths, 9 early stage of diabetes on dietary 
control alone (Table 3). Other concomitant medications of 101 (99%) “on metformin” and 26 
(96%) “not on metformin” diabetic patients at the time of diagnosis of vitamin B12 
deficiency were available for analysis. Twenty six percent of “on metformin” and 35% of 
“not on metformin” diabetic patients were on either PPI or H2B (p=0.815), 42% of “on 
metformin” and 23% of “not on metformin” diabetic patients were on antiplatelet agents, 
(p=0.083), 28% of “on metformin” and 12% of “not on metformin” diabetic patients were on 
lipid lowering agents (p=0.087), and 87% of “on metformin” and 69% of “not on metformin” 
diabetic patients were on antihypertensive agents and/or medications for ischaemic heart 
disease (p=0.028). 
3.4 Duration of metformin use in relation to development of vitamin B12 deficiency 
Of the 128 diabetic patients on metformin, 47 (37%) patients developed vitamin B12 
deficiency of all causes within 1 to 5 years of metformin use, 71 (55%) within 6 to 10 years, 
and 10 (8%) after 10 years, as shown in Figure 3 (i). Among these 128 patients, 102 (80%) 
patients had vitamin B12 deficiency of undetermined aetiology, and 26 (20%) had known 
causes. Of the 102 patients with undetermined aetiology, 31 (30%) developed overt vitamin 
B12 deficiency within 1 to 5 years of metformin use, 63 (62%) within 6 to 10 years, and 8 (8%) 
beyond 10 years, up to 30 years. Of the 26 patients with known causes, 16 (62%) developed 
vitamin B12 deficiency within 1 to 5 years of metformin use, 8 (31%) within 6 to 10 years, 
and 2 (8%) after 10 years. The relationship between the duration of metformin use and the 
development of vitamin B12 deficiency of undetermined and known causes was shown in 
Figure 3 (ii). The Extended Mantel-Haenzel chi-square analysis for linear trend was 4.74 (p = 
0.029 with one degree of freedom). 
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Fig. 3. Relationship between duration of metformin use and development of vitamin B12 
deficiency (i) of all causes (ii) of undetermined and known causes  
4. Conclusions 
4.1 Characteristics of vitamin B12 deficiency in type 2 diabetic patients  
The present study illustrates certain characteristics of vitamin B12 deficiency in adult 
Chinese patients with type 2 diabetes. Majority of the common causes of vitamin B12 
deficiency encountered in the general population such as PA, gastrointestinal diseases and 
nutritional deficiency also occur in type 2 diabetic patients. The frequencies of occurrence of 
these causes however differ between diabetic and non-diabetic patients. Vitamin B12 
deficiency of undetermined origin is more frequently encountered in diabetic than non-
diabetic patients (68% versus 30%), whereas PA, the most common definitive cause of 
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vitamin B12 deficiency, is more frequently detected in non-diabetic than diabetic patients 
(63% versus 30%). This preponderance of vitamin B12 deficiency of undetermined origin is 
even more conspicuous in diabetic patients on metformin than diabetic patients not on 
metformin (80% versus 47%). In this cohort of adult Chinese patients, the risk of developing 
vitamin B12 deficiency of undetermined origin is 5.5-fold higher in diabetic than non-
diabetic patients, and diabetic patients taking metformin have a 5.2-fold higher risk of 
developing vitamin B12 deficiency of undetermined origin than patients not taking 
metformin.   
This remarkable difference in the aetiological pattern of vitamin B12 deficiency between 
diabetic and non-diabetic patients accounts for the differences in the clinical manifestations 
of vitamin B12 deficiency between the two groups of patients. PA as an autoimmune disease 
causes profound gastric atrophy, IF depletion and vitamin B12 malabsorption, and is often 
accompanied by immune features; whereas conditions causing vitamin B12 deficiency of 
undetermined origin are often non-immune processes. They tend to cause a less severe 
degree of vitamin B12 malabsorption  and have a paucity of immune features. Diabetic 
patients with vitamin B12 deficiency of undetermined origin thus generally have a less 
severe degree of vitamin B12 deficiency, a less severe degree of anaemia, and less 
autoimmune features such as GPC and antithyroid antibodies, AITD, and autoimmune 
gastropathy compared with non-diabetic patients, as shown in the study. 
4.2 Implications of metformin use in type 2 diabetic patients 
4.2.1 Evidence of association of metformin use with vitamin B12 deficiency  
The finding of a greater proportion of type 2 diabetic patients especially those on metformin 
having vitamin B12 deficiency of undetermined origin in comparison with non-diabetic 
subjects implies the association of metformin use with vitamin B12 deficiency of 
undetermined origin. However, not all cases of vitamin B12 deficiency of undetermined 
origin are related to metformin. Vitamin B12 deficiency of undetermined origin actually has 
causative factors. Lack of easily available diagnostic tools bars the clarification or 
confirmation of these factors. In general, diagnostic approach to define the causes of vitamin 
B12 deficiency is first to look for nutritional deficiency and malabsorption syndromes 
notably PA and structural lesions of the stomach and intestine. These are the classical 
known causes of vitamin B12 deficiency. The previously less common or less well defined 
aetiologies of vitamin B12 deficiency, such as atrophic gastritis, gastric disease associated 
with Helicobacter pylori infection, gastric bypass for obesity, pancreatic insufficiency due to 
alcohol abuse, long-term use of metformin and acid-suppressive drugs like cimetidine, 
ranitidine, omeprazole, intestinal bacterial overgrowth, or even ageing and idiopathic, are 
principally diagnosed on clinical grounds and are grouped as vitamin B12 deficiency of 
undetermined origin, or now increasingly known as food cobalamin malabsorption, to be 
distinguished from the classical known causes (Clarke & Brown, 2003; Andres, 2008). 
Metformin-induced vitamin B12 deficiency is among one of the miscellaneous causes which 
are classified as “unknown” or “undetermined” simply because of lack of objective means to 
prove it as the sole agent or condition in the causation of vitamin deficiency.  
The present cohort study, comprising 186 type 2 diabetic patients with 128 on metformin, 
serves only to provide indirect evidence that metformin use constitutes a risk factor for the 
development of vitamin B12 deficiency, among other “unknown” factors which may also be 
present in these diabetic patients. The methodology adopted by the study is traditional - 
exclusion of the classical known causes. In this context, the study has the advantage that as 
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part of a previously reported longitudinal study of PA (Chan et al., 2008), all patients had 
documented vitamin B12 deficiency, had IF and GPC antibody assay performed, and had 
Schilling test done during the period when it was available. This diagnostic approach to 
arrive at the conclusion of metformin-induced vitamin B12 deficiency is similar to that cited 
in the other reports (Table 4, Table 5).  
In addition, the study attempted to include medications other than metformin in the 
analysis of risk factors. Two principal categories of drugs that have been commonly 
reported to have interaction with vitamin B12 are biguanides and acid suppressive therapy. 
PPI and H2B have been shown to suppress acid secretion by parietal cells and impair the 
absorption of protein bound dietary vitamin B12 and thus contribute to the development of 
vitamin B12 deficiency (Howden, 2000; Ruscin et al., 2002; Force et al., 2003; den Elzen et al., 
2008; Ali et al., 2009). The current evidence of vitamin B12 deficiency associated with long-
term PPI use however is based on small nonrandomized retrospective studies (Steinberg et 
al., 1980; Marcuard et al., 1994; Termanini et al.,1998; Hirschowitz et al., 2008). Overall the 
current collective body of information supports the notion that prolonged use of PPI notably 
in the elderly and in persons on high doses of PPI is associated with increased risk of 
vitamin B12 deficiency (Thomas et al., 2010). In the present study, evaluation of medications 
prescribed at the time of diagnosis of vitamin B12 deficiency showed no significant 
differences in the utilization rates of PPI/H2B, between diabetic and non-diabetic patients, 
and diabetic patients “on metformin” and “not on metformin”. There were also no 
significant differences in the utilization rates of other medications such as lipid lowering 
agents, anti-platelet agents, sulphonylureas and insulin between diabetic patients “on 
metformin” and “not on metformin”. As all patients in one group were exposed to 
metformin compared to none in the other group, metformin in the study emerged as the 
most likely culprit for medication-related vitamin B12 malabsorption. The antihypertensive 
and cardiovascular agents were significantly more frequently used by diabetic patients “on 
metformin” than those “not on metformin” in the study. This could be related to the longer 
diabetic history and the associated more cardiovascular complications in the group of 
patients on metformin. Although there are studies reporting longer diabetic history might 
predispose to the development of vitamin B12 deficiency (Pfipsen et al., 2009), there is 
insufficient data  for a definite conclusion to be drawn.  
Literature search found further evidence of metformin related vitamin B12 malabsorption. 
Impaired vitamin B12 absorption in patients who had been treated with metformin for up to 
3 months were first reported in 1969 (Berchtold et al., 1969). In the ensuing 4 decades, both 
observational and interventional studies unequivocally demonstrated the association 
between metformin use and vitamin B12 deficiency (Table 4). An observational study 
described malabsorption of vitamin B12 in  30% of diabetic patients during biguanide 
therapy (Adams et al., 1983). A cross-sectional study demonstrated a 22% prevalence of 
metabolically confirmed vitamin B12 deficiency in type 2 diabetic patients, with those on 
metformin exhibiting a statistically higher risk for B12 deficiency (Pflipsen et al., 2009). 
Another cross-sectional study demonstrated 6.9% of diabetic patients on metformin had low 
serum vitamin B12 level (Nervo et al., 2011). A case-control study demonstrated impaired 
gastrointestinal absorption in 30% and decreased serum B12 levels in 6% of patients in the 
metformin arm compared to none in the control arm (Tomkin et al., 1971). Another case-
control study similarly demonstrated significant falls in the mean serum B12 levels in the 
metformin arm compared to the control arm (Bauman et al., 2000). A nested case-control 
study comparing diabetic patients on metformin with and without vitamin B12 deficiency  
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Authors 
Report year 
Metformin 
duration 
Metformin 
dosage 
Outcome 
parameters 
No. of
patients on 
metformin
Study 
type 
Tomkin  
1971 
4-6 y1 
 
1.5-6g/d
 
control
*absorption B12↓
**serum B12↓ 
no change
*21/71 (30%)  
**4/71 (6%) 
19 on S5 
[2] 
Adams  
1983 
1-6 y
 
1-3g/d absorption B12 ↓ 14/46 (30%) [1] 
Bauman 2000 3 months
 
0.85-2.55g/d
 
control
mean serum B12↓
serum holoTCII2↓ 
no change
14 
 
7 on S5
[2] 
Wulffele 2003 16 weeks
 
0.85-2.55g/d
 
 
placebo 
mean serum 
B12↓: 16% 
HCy3↑: 8% 
B12↓: 2% 
HCy↑: 4%
171
 
 
182 on I6 
[3] 
Hermann 
2004 
mean 5.2 y
(range 1-18) 
mean 2.2 g/d
(range 0.85-3.4)
control
*serum B12↓
**serum HCy↑ 
no change
*12/53 (23%) 
**7/53 (13%) 
31 on S5 I6 D7 
[2] 
Pongchaidecha 
2004 
>6months -
 
control 
mean
serum B12 
 serum B12 
88 
64§ 
[2] 
Ting  
2006 
median 4 y
(IQR 2-5) 
median 2 y 
(IQR 1-4)
2.0±0.7g/d
 
1.4±0.7g/d 
mean serum B12↓
 
serum B12 normal 
155 
 
310  
[2] 
Sahin 
2007 
6 weeks -
control 
mean serum B12↓
no change 
165 [2] 
Pflipsen  
2009 
- - serum B12↓
±MMA4, HCy↑
44/195†(22%)  [1] 
Stehouwer 
2010 
4.3 y
 
 
 
2.05g/d
 
placebo 
mean serumB12↓:19%
serum HCy↑:26% 
mean serum B12↓:0% 
serum HCy↑:20% 
134 
 
146 on I6 
[3] 
Nervo 
2011 
median 4 y
(IQR 2-8.1)
1.7-2.55g/d serum B12↓ 10/144(6.9%) [1] 
1years   2holotranscobalamin II   3homocysteine   4methylmalonic acid  5sulphonylurea   6insulin   7diet     
[1] observational / cross-sectional study  [2] case control cohort study  [3] randomized placebo 
controlled study 
 ± metformin § no metformin 
Table 4. Studies investigating associations between metformin use and vitamin B12 
deficiency   
indicated both the dose and the duration of metformin use are risk factors for vitamin B12 
deficiency (Ting et al., 2006). Other cross-sectional cohort studies in Sweden, Thailand and 
Turkey also pointed to patients on metformin had lower serum B12 levels compared with 
thenon-exposed control group (Hermann et al., 2004; Pongchaidecha et al., 2004; Sahin et al., 
2007). Effects of short-term (16 weeks) and long-term (52 months) treatment with metformin 
on the serum concentrations of vitamin B12 in type 2 diabetic patients were investigated by 
a Dutch randomized placebo controlled trial and showed both short- and long-term use of 
metformin increased the risk of vitamin B12 deficiency (Wulffele et al., 2003; Stehouwer et 
al., 2010). All these studies defined vitamin B12 deficiency based on biochemical markers 
and did not evaluate the clinical importance.   
P=0.011
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Concerning reports on the clinical manifestations of metformin-related vitamin B12 
deficiency in diabetic patients (Table 5), there are case reports of megaloblastic anaemia 
related to long-term metformin treatment causing vitamin B12 deficiency (Callaghan et al., 
1980; Gilligan, 2002; Liu et al., 2006; Lin et al., 2007). A case series showed metformin-related 
megaloblastic anaemia accounted for 6% (10/162) of all vitamin B12 deficiency patients 
(Andres et al., 2002), and another case series revealed a 9% prevalence (54/600) of 
megaloblastic anemia in diabetic patients taking long-term biguanides (Filioussi et al., 2003). 
Neurological deficits due to vitamin B12 deficiency manifest chiefly as peripheral 
neuropathy, subacute combined cord degeneration, and cognitive impairment. There are 
case reports of subacute combined degeneration and peripheral neuropathy related to 
metformin therapy (Liu et al., 2006; Bell, 2010), and a prospective case-control study 
demonstrating diabetic patients with concurrent symptomatic peripheral neuropathy had 
lower serum B12 levels and more severe neuropathy in the metformin treatment group in 
comparison with non-metformin treated patients (Wile & Toth, 2010).  
 
Authors 
Report 
year 
Metformin 
duration 
Metformin 
dosage 
Presenting 
features 
 
No. of
patients 
on 
metformin
Tests 
Metformin 
off/ 
continued 
B12 
Study 
type 
Callaghan  
1980 
8 y1 1g/d MA2 1 Schill5  continued inj10 [4] 
Gilligan  
2002 
5 y - MA 1 Schill 
IF6 
off oral [4] 
Andres  
2002 
8.9±3.4 y 
range 3-10 
2.015±
0.45g/d 
range 1.4-2.5
MA 
 
10  Schill 
IF 
continued:8 
off:2 
inj:4 
oral:6 
[5] 
Filioussi  
2003 
11.8±3.6 y - MA 54/600 
(9%) 
GPC7 continued Route 
NM 
[5] 
Liu  
2006 
*>10 y 
 
**8 y 
-
- 
*SCD3, 
dementia 
**MA 
1
 
1
IF
 
IF GPC 
off
 
off
inj 
 
inj 
[4] 
Lin 2007 6 y 1g/d MA DVT4 1 GPC off inj [4] 
Wile  
2010 
>6 months 
 
 
total 3389.5g
 
 
control 
mean B12 ↓, 
more severe 
neuropathy 
normal B12, 
less severe 
neuropathy
59  
 
 
63 † 
   [6] 
Bell  
2010 
3 y - peripheral 
neuropathy 
1 IF 
CD8 
NM9 inj [4] 
1years    2megaloblastic anaemia   3subacute combined degeneration  4deep vein thrombosis  5Schilling 
test   6intrinsic factor antibody   7gastric parietal cell antibody  8celiac disease ruled out    9not mentioned    
10injection   on sulphonylurea/insulin [4] case report  [5] case series   [6] prospective case control study 
Table 5. Reports of metformin-related symptomatic vitamin B12 deficiency 
B12 malabsorption associated with long-term metformin treatment (Callaghan et al., 1980; 
Gilligan, 2002; Liu et al., 2006; Lin et al., 2007). A case series showed metformin-related 
megaloblastic anaemia accounted for 6% (10/162) of all established vitamin B12 deficiency 
patients (Andres et al., 2002), and another case series revealed a 9% prevalence (54/600) of 
megaloblastic anemia in diabetic patients taking long-term biguanides (Filioussi et al., 2003). 
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Neurological deficits due to vitamin B12 deficiency manifest chiefly as peripheral 
neuropathy, subacute combined cord degeneration, and cognitive impairment. There are 
case reports of subacute combined degeneration and peripheral neuropathy related to 
metformin therapy (Liu et al., 2006; Bell, 2010), and a prospective case-control study 
demonstrating diabetic patients with concurrent symptomatic peripheral neuropathy had 
lower serum B12 levels and more severe neuropathy in the metformin treatment group 
compared with non-metformin treated patients (Wile & Toth, 2010). 
4.2.2 Duration and dosage of metformin use in relation to onset of vitamin B12 
deficiency 
From the present study, for diabetic patients on metformin, about 30% developed vitamin 
B12 deficiency of undetermined origin within 5 years of metformin use, and 60% within 6 to 
10 years; and for those with known causes especially those with PA, 60% within the first 5 
years, and 30% within 6 to 10 years. The main determining factor in the latter group of 
patients was probably the known cause, e.g. PA, and whether metformin use contributed to 
or hastened the development of vitamin B12 deficiency in these patients is difficult to 
determine at this stage. Due to the retrospective nature of data collection concerning 
diabetic control and medications, precise analysis of metformin duration and dose in 
relation to the development of vitamin B12 deficiency is beyond the capacity of the present 
study. One practical message is that clinicians should be aware of the development of 
vitamin B12 deficiency with both short-term and long-term use of metformin ranging from 1 
year to beyond 10 years. An equally important message corollary to this is that known 
causes of vitamin B12 deficiency such as PA occur in diabetic patients as in non-diabetic 
subjects, and the same diagnostic approach to delineate the underlying cause of vitamin B12 
deficiency should be adopted for diabetic patients as for other patients in general.  
From the reports in the literature (Table 4), diminished absorption of vitamin B12, 
manifested as decreased serum B12 levels, occurred as early as 3 to 4 months after the use of 
metformin (Bauman et al., 2000; Wulffele et al., 2003). Symptomatic deficiency of the 
vitamin, according to most reports (Table 5), occurred 5 to 10 years after the use of 
metformin. This is in line with the established knowledge that the body store of vitamin B12 
is huge (2500 μg) in comparison to daily loss/requirement (1-2 μg) (Carmel, 2008), and 
depletion of the pre-existing body store vitamin thus takes 12 to 15 years. The process of 
exhaustion of body store will be hastened in the presence of other predisposing factors for 
vitamin B12 deficiency such as partial gastrectomy.  
Two recent reports concerning metformin-related vitamin B12 deficiency suggested need for 
improved management of such patients. The increased risk of vitamin B12 deficiency with 
metformin use was re-emphasized by a nested case-control study of Chinese patients (Ting 
et al., 2006). It showed correlation between the dose and duration of metformin use with 
vitamin B12 deficiency. Compared with those receiving metformin for less than 3 years, the 
adjusted OR was 2.39 (95% CI, 1.46-3.91) for those using metformin for 3 years or more. 
After excluding subjects with borderline vitamin B12 concentrations, the metformin dose 
remained the strongest independent predictor of vitamin B12 deficiency. Each 1-g/day 
increment in metformin dose conferred an OR of 2.88 (95% CI, 2.15-3.87) of developing 
vitamin B12 deficiency. In a prospective randomized placebo controlled trial, the Dutch 
scientists found the fall in serum B12 levels with metformin persists and becomes more 
apparent with time (Stehouwer et al., 2010). It is reasonable to assume that harm will 
eventually occur in some patients with metformin-induced low vitamin B12 levels. 
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4.2.3 Treatment of metformin-induced vitamin B12 deficiency 
There is no consensus on optimal treatment of metformin-induced vitamin B12 deficiency. 
In the present study, metformin was continued unless there were other reasons for 
discontinuation or switching to other anti-diabetic therapy such as renal insufficiency or 
poor glycaemic control. Vitamin B12 replacement was given intramuscularly, daily, 
monthly, and then 3-monthly as maintenance. Most authors of the case reports/series (Table 
5) treated their patients’ metformin-induced megaloblastic anaemia with vitamin B12 either 
orally or parenterally at 1000 µg daily or on alternate days initially, and continued 
metformin therapy (Callaghan et al., 1980; Andres el al., 2002; Filioussi et al., 2003). In all 
these cases the anaemia responded but the neuropathy of one patient persisted (Bell, 2010). 
In general, two aspects of treatment have to be considered. Vitamin B12 replacement is 
mandatory and can be given either intramuscularly or orally. Parenteral route may be 
preferred for subjects with neurological deficits due to the potential risk of irreversibility. 
The rationale for oral vitamin B12 replacement is that there is evidence for an alternative 
pathway of vitamin B12 absorption that does not require IF or the presence of an intact 
ileum (Berlin et al., 1968; Kuzminski et al., 1998; Andres et al., 2008). For both routes of 
administration, large doses of crystalline cobalamin in the range of 1000 µg should be given. 
The duration of vitamin B12 supplementation depends on the removal of the triggering 
factor. If metformin is continued, appropriate vitamin B12 replacement should be 
administered. Although malabsorption of vitamin B12 is reversible 2 to 8 weeks after 
stopping metformin therapy (NeLM, 2005), withdrawal of metformin is not mandatory in 
view of its efficacy and safety, and most of the complications of vitamin B12 deficiency are 
remediable apart from irreversible damage to the central and peripheral nervous system 
which may occur if treatment is delayed.  
Up to now, the mechanism of metformin-related vitamin B12 malabsorption is still not fully 
understood. Metformin causes fall in blood glucose primarily through suppression of 
hepatic gluconeogenesis, enhancement of insulin sensitivity, and reduction of 
gastrointestinal absorption of glucose. This action is achieved through reduction of 
efficiency of ion exchange across cell membranes which is brought about through activation 
of AMP-activated protein kinase and perhaps other enzymes. This mode of action also 
underlies the untoward side effects of increased intestinal motility and lactic acidosis. 
Whether the process of malabsorption of vitamin B12 is also similarly mediated is unclear. 
Currently the most likely mechanism is impaired uptake of vitamin B12-intrinsic factor 
complex at the ileal cell membrane receptors. This uptake has been shown to be a calcium 
dependent process (Bauman et al., 2000). The hydrophobic tail of metformin extends into the 
hydrocarbon core of cell membrane and the protonated metformin group gives a positive 
charge to the membrane surface and displaces divalent cations. Thus by altering the 
membrane potentials and affecting the divalent cation membrane functions, especially those 
calcium-dependent ones, metformin may act as a calcium channel blocker. This postulation 
is supported by studies showing reversal of malabsorption by increasing calcium intake 
(Bauman et al., 2000). Other studies showed the malabsorption might be related to 
decreased IF secretion (Adams et al., 1983), or delay in intestinal transit and bacterial 
overgrowth in diabetic patients. Some studies however failed to show bacterial overgrowth 
in such patients (Bauman et al., 2000). Further research is required to clarify the mode of 
metformin-induced malabsorption of vitamin B12.  
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4.3 Future direction  
The prevalence of vitamin B12 deficiency is expected to increase with time in view of the 
ageing population and the more widespread use of sensitive metabolite assays to detect 
subtle cobalamin deficiency. Among the population over the age of 60, the prevalence of 
metabolically confirmed vitamin B12 deficiency ranges from 12% to 23% (Pennypacker et al., 
1992; Lindenbaum et al., 1994; Johnson et al., 2003). Type 2 diabetes, at the same time, is 
becoming more common almost everywhere in the world. The global prevalence of type 2 
diabetes is 2.8% ( 171 million people) in 2000 (Wild et al., 2004), 6.6% (285 million) in 2010, 
and will be reaching 7.8% (438 million) in 2030 (The Diabetes Atlas, 2009). The global 
prevalence of age-standardized adult diabetes, according to a recent large international 
study, was 9.8% (8.6-11.2) for men, and 9.2% (8.0-10.5) for women in 2008 (Danaei et al., 
2011). In Hong Kong, the prevalence of type 2 diabetes in elderly subjects above the age of 
60 is estimated to range between 9.8% (Woo et al., 1987) and 10.7% (Kung et al., 1996), and 
the age-standardized prevalence of type 2 diabetes for the 35-64 age group was 9.5% for 
men and 10.2% for women (Lam et al., 2000). 
(new paragraph) Concerning anti-diabetic therapy, metformin remains one of the two oral 
anti-diabetic drugs in the WHO model list of essential medicine in 2010, in spite of  a large 
array of new therapeutic agents available in the pharmaceutical market. It is the only anti-
diabetic drug that has been conclusively shown to prevent the cardiovascular complications 
of diabetes. The drug remains active after months or years of therapy and its efficacy is little 
dependent on the residual effective β-cell mass. It causes less weight gain and fewer 
hypoglycaemic attacks compared with sulphonylureas and insulin. It is now recommended 
as the initial therapy for type 2 diabetes by the National Institute for Health and Clinical 
Excellence of the United Kingdom, the American Diabetes Association, and the European 
Association for the Study of Diabetes. As metformin has been available in the United 
Kingdom since 1958, in Canada since 1972, in the United States since 1995, and for over 40 
years in Hong Kong, the pool of diabetic patients with metformin-induced vitamin B12 
deficiency, diagnosed or undiagnosed, could be considerable in the present era. 
Concomitant occurrence of two comorbid conditions, diabetes and vitamin B12 deficiency, 
in one subject is apparently undesirable. Florid deficiency of vitamin B12 is accompanied 
and actually preceded by reciprocal rise of homocysteine levels imposing an increased risk 
of cardiovascular complications (Hoogeveen et al., 2000; The Homocysteine Studies 
Collaboration, 2002). Neurological deficits, one of the major manifestations of vitamin B12 
deficiency can often be diagnostically confused with diabetic neuropathy, one of the long-
term microangiopathic complicaitons of diabetes. Clinicians should therefore have a high 
index of suspicion for metformin-induced vitamin B12 deficiency in diabetic patients.  
To prevent vitamin B12 deficiency, it is reasonable to consider formulating appropriate 
screening strategy for diabetic patients on metformin. According to the WHO’s criteria,  a 
condition is worthwhile screening if it  is an important health problem, if there are simple 
tests available to detect the condition at an early and treatable stage, and if effective and safe 
treatment is available (Wilson & Junger, 1968). The condition of vitamin B12 deficiency 
fulfills these criteria. Before such screening guidelines are available, appropriate preventive 
measures may be instituted. These may include monitoring of vitamin B12 levels at regular 
intervals such as annually or biannually; or giving vitamin B12 prophylactically as dietary 
supplement or more conveniently as annual injection at 1000 µg, a dose sufficient to cover 
vitamin B12 needs for at least a year. 
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